Poor prognosis of ovarian cancer with large cell neuroendocrine carcinoma: Case report and review of published works

Asada, Kenichi; Kawana, Kei; Teshima, Shin‐ichi; Saito, Ako; Kawabata, Masakiyo; Fujii, Tomoyuki

doi:10.1111/jog.12235

Cited by 11 publications

(9 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inconsistent outcomes regarding the prognostic significance of NAC may be related to the failure to consider tumor grade, histotype, stage, and chemotherapy response [27–32]. In the current study, we identified optimal IDS and prognosis-related factors in advanced HG-EOC patients who underwent NAC.…”

Section: Discussionmentioning

confidence: 87%

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer

Deng

et al. 2016

J Ovarian Res

View full text Add to dashboard Cite

BackgroundNo consensus exists on the outcome-related factors of interval debulking surgery (IDS) in patients with advanced high-grade serous ovarian cancer (HG-SOC) who underwent neoadjuvant chemotherapy (NAC). This study aimed to explore the optimal timing for IDS and the prognosis-associated factors of International Federation of Gynecology and Obstetrics stage IIIc to IV HG-SOC patients.MethodsA total of 160 IIIc to IV stage HG-SOC patients were retrospectively analyzed. Patients with large volume ascites underwent NAC and subsequent IDS from the Jiangsu Institute of Cancer Research between 1993 and 2013. The outcome of IDS-associated factors was explored by logistic regression. To predict IDS outcome, the potential values of serum CA-125 levels and CA-125 decreasing kinetics were determined by the receiver operating characteristic curve. The associations between survival durations and covariates were assessed by Cox proportional hazards model and log-rank test.ResultsOptimal IDS was achieved in 80.6% of HG-SOC patients who underwent NAC. Multivariate analyses revealed that ascites regression (p = 0.01), serum CA-125 level (p = 0.02), and CA-125 decreasing kinetics (p = 0.01) were independent optimal IDS predictors. CA-125 decreasing kinetics, IDS outcome, and ascites volume were independently associated with overall survival (OS) (p = 0.04, p < 0.01, p = 0.03, respectively) and progression-free survival (PFS) (p < 0.01, p < 0.01, p = 0.02, respectively). Patients who exhibited disappearance of ascites (<500 ml) had longer PFS (19.7 months vs.14.9 months) and OS (32.1 months vs. 26.0 months) than patients who exhibited residual ascites (≥500 ml). Subsets with higher CA-125 decreasing kinetics (≥2.2) had longer PFS (21.4 months vs.13.1 months) and OS (29.6 months vs.26.8 months) than counterparts (kinetics < 2.2).ConclusionsAscites regression and CA-125 decreasing kinetics were independently associated with surgical outcome and prognosis in advanced HG-SOC patients who underwent NAC.

show abstract

Section: Discussionmentioning

confidence: 87%

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer

Deng

et al. 2016

J Ovarian Res

View full text Add to dashboard Cite

show abstract

“…LCNEC is a type of neuroendocrine tumour that can affect lungs, gall bladder,7 urinary bladder,8 head and neck,9 prostate,10 ovary,11 uterine cervix,12 vagina,13 endometrium,14 breast,15 colon,16 ileum,17 rectum,18 bile ducts,19 stomach,20 renal pelvis,21 skin,22 thymus,23 etc. Pulmonary neuroendocrine tumours make up to 20% of all lung cancers of which LCNEC are 10% (ie, 2–3% of all lung cancers).…”

Section: Discussionmentioning

confidence: 99%

Ectopic ACTH-producing large cell neuroendocrine Pancoast tumour presenting as Horner syndrome

Verma¹,

Lambert

Katz

et al. 2017

BMJ Case Reports

View full text Add to dashboard Cite

We present an interesting case where a patient is presented with a droopy left eyelid (as part of Horner syndrome) and Cushingoid features which were a result of a Pancoast tumour (apical lung tumour in superior pulmonary sulcus) involving the left lung. This tumour was secreting ectopic adrenocorticotropic hormone (ACTH), a paraneoplastic endocrine phenomenon, which resulted in Cushing syndrome symptomatology. Though most ectopic ACTH-producing lung cancers are either small cell or carcinoid tumours, this was in fact a large cell neuroendocrine cancer (LCNEC). Patient underwent surgical resection and adjuvant/neoadjuvant chemotherapy with radiation; however, he succumbed to LCNEC given aggressive nature of the disease.

show abstract

“…LCNEC is usually accompanied by other epithelial and germ tumor, pure LCNEC is extremely rare [5][6][7][8] . Despite extensive surgery and adjuvant chemotherapy performed for this type of tumor, the prognosis is common poor in the published literatures, even when diagnosis is made at an early stage [3,9,10] . Here, we present a case of a 37 year old woman who was diagnosed with stage IIIA1 LCNEC of the ovary.…”

Section: Introductionmentioning

confidence: 99%

An Ovarian Large-Cell Neuroendocrine Carcinoma Accompanied by Clear Cell Carcinoma with Specific High Level of AFP: Case Report and Review of the Literature

Jian

Yao

Zhu

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Large cell neuroendocrine carcinoma (LCNEC) is a rare histological subtype of ovarian cancer. A few cases have been reported in literature with high invasiveness and poor prognosis. However, there still have not accepted criteria for diagnosis and treatment of LCNEC. Case presentation: We report an unmarried 37 year-old woman who was diagnosed with LCNEC associated with clear cell carcinoma and the tumor index was manifested with a specific increase of AFP. The case received six courses of Etoposide and carboplatin chemotherapy as an adjuvant therapy after primary curative surgery. However, she relapsed within 6 months after surgery and metastasized rapidly to distant organs despite combination chemotherapy of paclitaxel, cisplatin and bevacizumab and died 18 months after primary sugery. Conclusions This is the first reported case of LCNEC manifested with a specific increase of AFP and characteristically metastased to the spine as recurrence. Since LCNEC present with aggressive malignancies and can easily metastasize to distance place through hematogenous approach, we recommend that adding Bevacizumab in primary chemotherapy may be beneficial to extend disease-free survival. Further research are needed to find the best treatment of LCNEC so as to improve the prognosis of patients.

show abstract

Poor prognosis of ovarian cancer with large cell neuroendocrine carcinoma: Case report and review of published works

Cited by 11 publications

References 17 publications

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer

Ectopic ACTH-producing large cell neuroendocrine Pancoast tumour presenting as Horner syndrome

An Ovarian Large-Cell Neuroendocrine Carcinoma Accompanied by Clear Cell Carcinoma with Specific High Level of AFP: Case Report and Review of the Literature

Contact Info

Product

Resources

About